Woodline Partners
ATRA icon

Woodline Partners’s Atara Biotherapeutics ATRA Stock Holding History

Woodline Partners’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-70,889
Closed -$603K – 603
2024
Q2 		$603K Sell
70,889
-103
-0.1% -$1.55K 0.01% 490
2024
Q1 		$1.23M Buy
+70,992
New +$1.26M 0.01% 450

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Woodline Partners's ATRA Position: Q3 2024 in Review

Woodline Partners sold out of Atara Biotherapeutics (ATRA) in Q3 2024, closing a stake of 70,889 shares — an estimated $603K sold.

Woodline Partners first reported a position in ATRA in Q1 2024 and held it in 2 quarters. The position peaked at $1.23M in Q1 2024. 35 funds tracked by Wall St. Rank hold ATRA as of Q3 2024.

  • Woodline Partners reported no remaining Atara Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Woodline Partners sold 70,889 Atara Biotherapeutics shares in Q3 2024, an estimated $603K.
  • Woodline Partners first reported a position in Atara Biotherapeutics in Q1 2024 and held it in 2 quarters.
  • Woodline Partners's Atara Biotherapeutics position peaked at $1.23M in Q1 2024.
  • 35 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2024.

Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.